Trail Receptors: Targets for Cancer Therapy

  • Robin C. Humphreys
  • Wendy Halpern

A human tumor cell's ability to avoid the normal regulatory mechanisms of cell growth, division, and death are the hallmarks of transformation and cancer. Numerous novel therapeutic agents currently in preclinical or clinical evaluation aim to revive the normal regulation or evade these regulatory defects and induce growth arrest and cell death. One of the cell death pathways that has garnered significant interest, as a potential target for therapeutic intervention, is the programmed cell death pathway regulated by the tumor necrosis factor-related apoptosis-inducing ligand receptors (TRAIL-RS). Receptor agonist molecules including forms of the native ligand and monoclonal antibodies are being developed and tested as therapeutics in the treatment of human cancer.


apoptosis monoclonal antibody agonist TRAIL TRAIL receptor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science + Business Media B.V 2008

Authors and Affiliations

  • Robin C. Humphreys
    • 1
    • 2
  • Wendy Halpern
    • 3
  1. 1.Development Sciences and ResearchHuman Genome SciencesRockvilleUSA
  2. 2.Oncology Research DepartmentHuman Genome SciencesRockvilleUSA
  3. 3.Human Genome Sciences, Pathology, Pharmacokinetics and ToxicologyRockvilleUSA

Personalised recommendations